Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025

Page 8 of 14

7. Neuronetics Inc (NASDAQ:STIM)

Number of Hedge Fund Holders In Q3 2024: 9

Neuronetics Inc (NASDAQ:STIM) has medical products that use transcranial magnetic stimulation to treat major depressive disorder and anxiety.

The stock has surged so far in 2025 due to it completing the acquisition of Greenbrook TMS. It integrated NeuroStar’s tech with Greenbrook’s network of 95+ U.S. clinics.

The company projects $22 million in annualized cost synergies with 90% already implemented. Moreover, pro forma 2024 revenue reached $129.8 million. This is up from a standalone $74.5 million, and it has 2025 revenue guidance at $145 million to $155 million.

The consensus price target of $4.67 implies 44.03% upside.

STIM stock is up 99.9% year-to-date.

Page 8 of 14